The benefit of evolocumab treatment is consistent regardless of inflammation level HR 0.82 0.93 0.80 95%CI 0.70-0.95 0.83-1.05 0.71-0.90 ARR 1.6% 1.8%

Slides:

Advertisements

Similar presentations

Trial profile Fox K et al. Lancet 2008;372:

Advertisements

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Clinical Outcomes with Newer Antihyperglycemic Agents

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.

Clinical Outcomes with Newer Antihyperglycemic Agents

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Discontinuation of medication after nonfatal event: MI

Clinical Outcomes with Newer Antihyperglycemic Agents

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

LEADER trial: Primary Outcome

The European Society of Cardiology Presented by Dr. Bo Lagerqvist

Clinical need for determination of vulnerable plaques

Pravastatin in Elderly Individuals at Risk of Vascular Disease

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

First time a CETP inhibitor shows reduction of serious CV events

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

51st Annual Scientific Session for the LIFE Investigators

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Baseline characteristics of patients

LIFE: Reduction in primary end-point events seen with reduction of LVH by two electrocardiographic criteria End point % reduction with each 1050-mm x ms.

Diabetes Journal Club March 17, 2011

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Cystatin C levels and risk of death from all causes

Mintu P. Turakhia et al. JACEP 2016;2:

DECLARE-TIMI 58.

Svend A. Mortensen et al. JCHF 2014;2:

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Berger JS, et al. JAMA 2009;301:

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

Comparison of Baseline Characteristics by Primary End Point

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

Christian Madelaire et al. JCHF 2018;6:

FIELD: Primary outcome

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Pamela E. Scott et al. JACC 2018;71:

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Increase of physical activity over time associated with lower HF risk

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Javier Escaned et al. JCIN 2018;11:

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Cardioprotective effects of ivabradine administration in the setting of acute coronary syndromes and myocardial infarction. Cardioprotective effects of.

Presentation transcript:

The benefit of evolocumab treatment is consistent regardless of inflammation level HR 0.82 0.93 0.80 95%CI 0.70-0.95 0.83-1.05 0.71-0.90 ARR 1.6% 1.8% 2.6% (*) Primary endpoint: composite of CV death, MI, stroke, hospitalization for UA, or coronary revascularization KM: Kaplan-Meier; hsCRP: high-sensitivity C-reactive protein; CV: cardiovascular; MI: myocardial infarction; UA: unstable angina; HR: hazard ratio; CI: confidence interval; ARR: absolute risk reduction. Bohula EA, et al. Circulation 2018